Onconetix ONCO · USD

ENTADFI program, effective April 30, 2024, with such individuals to continue assisting the Company on an as-needed, consulting basis.

By Realbotix if a Buyer Adverse Recommendation Change (as defined in the Share Exchange Agreement) occurs prior to receipt of Buyer stockholder approval.

By us in connection with entering into a definitive agreement for a Buyer Superior Proposal (as define in the Share Exchange Agreement).

By us if the audited Realbotix financial statements have not been delivered by April 30, 2026.

In the event of a termination of the Share Exchange Agreement by Realbotix for failure to satisfy the Net Cash Condition, if Net Cash at the time of termination would be greater than $5.0 million (assuming the consummation of any Transaction Financing pursuant to Financing Agreements), we are obligated to pay Realbotix’s transaction expenses, with such transaction expenses not to exceed $500,000.

Exchange Agreement agreed to use its commercially reasonable efforts to consummate the Realbotix Transaction.

The aggregate fair value of the common and preferred shares issued as consideration was equal to approximately $65.1 million.

Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗